Compare Alcon AG (ALC) vs Garmin Ltd. (GRMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Garmin Ltd. — how do they compare? Alcon AG trades at $66.96 (market cap $32.69B), while Garmin Ltd. trades at $242.08 (market cap $47.96B). The key difference: Garmin Ltd. is the larger of the two by market cap, and Garmin Ltd. pays the higher dividend (1.69%). Which is the better fit depends on your goals.
| ALC | GRMN | |
|---|---|---|
Market Cap | $32.69B | $47.96B |
Sector | Health | Technology |
52-Week High | $92.22 | $267.52 |
52-Week Low | $62.02 | $187.10 |
Enterprise Value | $36.28B | $45.43B |
Dividend Yield | 0.54% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Garmin (GRMN) trades at $248.68, up 3.63% today, reflecting strong momentum near its recent highs. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 23.26% net income margin and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent product launches like LiveScope 2 and positive earnings beats in Q4 2025 and Q1 2026 underscore operational strength.
The outlook remains favorable with a consensus price target of $282.67, though risks include competitive pressures and market volatility. Investment appeal centers on sustained profitability and innovation, but investors should weigh high valuation multiples against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
